Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Hoppner, J; Kornak, U; Hogler, W; Obermayer-Pietsch, B; Rutsch, F; Oheim, R; Grasemann, C.
Hypophosphatemic Rickets: Diagnostic Approach and current Treatments in Childhood.
OSTEOLOGIE. 2020; 29(04): 293-301. Doi: 10.1055/a-1257-8108
Web of Science FullText FullText_MUG

Co-authors Med Uni Graz: Obermayer-Pietsch Barbara
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Rickets is caused by an undersupply of calcium and/or phosphate to the growing body. The calcium- phosphate metabolism is regulated by the secosteroid hormone calcitriol, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23). Excessive FGF23 action results in reduced renal phosphate reabsorption, and subsequent hypophosphataemia, undermineralization of bone, teeth and growth plates and the phenotype of hypophosphatemic rickets ( HR)/osteomalacia. The most common form of FGF23-dependent HR is X-linked hypophosphatemic rickets (XLH), which was traditionally treated via supplementation of phosphate and active vitamin D only. Since 2018, a monoclonal antibody against FGF23, Burosumab, is available for the therapy of XLH in children. The new therapy has the potential to improve long-term complications, growth and quality of life; such data are currently being collected in registries. Support groups for German-speaking people affected by XLHinclude Phosphatdiabetes e.V. and www.phosphatdiabetes.at.
Find related publications in this database (Keywords): Phosphate metabolism; FGF23; hypophosphatemic rickets; burosumab